In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Conjugate Adipotide | Synthetic analog Liraglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Conjugate | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 5 | 4,766 | |
| Evidence level | Results from animal studies onlyRegistered trials, no results from human studies | Has results from studies in people | |
| Safety | |||
| Safety results | 1 (0 in people) | 805 (793 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 1 | 469 · 30 active49 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 1. The FDA, the EMA and the other sources we use show no approval (as of 13 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Adipotide | Liraglutide |
|---|---|---|
| Glycemic controlMetabolic and weight | 11 | 1,1171067491 |
| Body weight |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Victoza says: “Adults, adolescents and children 10 years and older with insufficiently controlled type 2 diabetes, as an adjunct to diet and exercise”
11 |
83481717 |
| Kidney functionKidney and urinary | 11 | 1049932 |
|---|
| Receptor activity and mechanismMetabolic and weight | 11 | 8250626 |
|---|
| Body compositionMetabolic and weight | 11 | 4747 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Liraglutide differs from Glucagon-like peptide 1 (7-37) at 1 position and carries 1 added group.
What is different
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)
M.D. Anderson Cancer Center4 participants24 May 2012 to 2 Jan 2019
Prostate Cancer
Top 3 of 469 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S9,341 participants31 Aug 2010 to 17 Dec 2015
Diabetes · Diabetes Mellitus, Type 2
GRADE Study Group7,850 participantsMay 2013 to 30 Apr 2021
Type 2 Diabetes · Comparative Effectiveness of Glycemia-lowering Medications
Novo Nordisk A/S3,731 participants1 Jun 2011 to 2 Mar 2015
Metabolism and Nutrition Disorder · Obesity
49 more mention it but do not test it. They only measure it or name it in their text.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Adipotide | Liraglutide |
|---|---|---|
| Glycemic controlEndocrine and hormonesCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −1.09% HbA1c difference Dose studied: 1.8 mg once daily26 weeksn = 3442009 |
| Body weightMetabolic and weightCompared as: difference from placebo, in sds | No randomized trial result 1 result from other study designs. | −0.22 SDS Estimated difference in BMI SDS Dose studied: 3.0 mg56 weeksn = 2512020 |
| Body compositionMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −0.24% Treatment difference Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024 |
| Kidney functionKidney and urinaryCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | −32% UAER reduction · Shown as a change. The study reports a uaer reduction of this size. Dose studied: 1.8 mg/d12 weeksn = 272017 |
| Receptor activity and mechanismCardiovascularCompared as: difference from placebo, in proteins | No randomized trial result 1 result from other study designs. | 124 proteins Proteins modulated Dose studied: 3 mg daily5 weeksn = 202026 |
No randomized trial result
1 result from other study designs.
−1.09%
HbA1c difference
Dose studied: 1.8 mg once daily26 weeksn = 3442009
No randomized trial result
1 result from other study designs.
−0.22 SDS
Estimated difference in BMI SDS
Dose studied: 3.0 mg56 weeksn = 2512020
No randomized trial result
1 result from other study designs.
−0.24%
Treatment difference
Dose studied: 3.0 mg target dose, once daily40 weeksn = 1282024
No randomized trial result
1 result from other study designs.
−32%
UAER reduction · Shown as a change. The study reports a uaer reduction of this size.
Dose studied: 1.8 mg/d12 weeksn = 272017
No randomized trial result
1 result from other study designs.
124 proteins
Proteins modulated
Dose studied: 3 mg daily5 weeksn = 202026